UBS analyst AJ Rice raised the firm’s price target on Tenet Healthcare (THC) to $288 from $260 and keeps a Buy rating on the shares. Tenet Healthcare posted solid results for the quarter and is well-positioned for 2026 despite Exchange subsidy noise, the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on THC:
- Tenet Healthcare price target raised to $260 from $240 at BofA
- Tenet Healthcare price target raised to $242 from $230 at TD Cowen
- Tenet Healthcare price target raised to $260 from $247 at Morgan Stanley
- Tenet Healthcare price target raised to $277 from $253 at RBC Capital
- Tenet Healthcare price target raised to $250 from $225 at KeyBanc